Hamilton Global Opportunities plc (ALHGO.PA) Published Its 2024 Full-Year Financial Results and Activity Report
-- Highlights for 2024: -- HGO raised a total of EUR12.5 million of capital through two issues of shares and an inaugural debt issue in US$. -- New investment in AntariaPharma a tech-enabled, alternative lending platform specialised in pharmacies -- Additional investment in Gauzy Ltd a world leader in smart glass and ADAS technologies in March 2023, and subsequent IPO of Gauzy Ltd on the NASDAQ -- Financial elements: -- Profit after tax of EUR605,781 -- Earnings per share EUR0.96 -- NAV per share EUR37.05 -- Cash & cash equivalents EUR1,000,096 -- Net assets of EUR23,282,172 as of December 31, 2024 LONDON--(BUSINESS WIRE)--April 29, 2025--
Regulatory News:
Hamilton Global Opportunities plc (GB00BMDXQ672 - ALHGO) publishes its annual results for 2024, approved by the Board of Directors on April 24, 2025, and its annual financial report, which is available on the company's website in the Investors section (hamiltongo.eu) and on the AMF website.
Gustavo Perrotta, Founder and CEO of Hamilton Global Opportunities, said:
"As we enter the fourth full year since our listing on the Euronext Growth market we are pleased to have retained the confidence of our investors which has been confirmed by the different capital raising initiatives in 2024. This additional capital has allowed us to not only continue to support our existing portfolio companies but also to add an investment in Antaria Pharma which complements the existing portfolio."
PERFORMANCE Assets as at 31 December 2024 (in EUR) ------------------ ------------------ December 31, 2024 December 31, 2023 -------------------------------------- ------------------ ------------------ Non-current assets -------------------------------------- ------------------ ------------------ Tangible assets 86 449 2 240 -------------------------------------- ------------------ ------------------ Investments 24 426 261 12 744 153 -------------------------------------- ------------------ ------------------ Trade and other receivables 57 100 57 100 -------------------------------------- ------------------ ------------------ Total non-current assets 24 569 810 12 803 493 -------------------------------------- ------------------ ------------------ Current assets -------------------------------------- ------------------ ------------------ Trade and other receivables 66 896 269 860 -------------------------------------- ------------------ ------------------ Cash and cash equivalents 1 000 096 853 249 -------------------------------------- ------------------ ------------------ Financial Assets 1 535 456 0 -------------------------------------- ------------------ ------------------ Total current assets 2 602 448 1 123 109 -------------------------------------- ------------------ ------------------ Total assets 27 172 258 13 926 602 -------------------------------------- ------------------ ------------------ Liabilities -------------------------------------- ------------------ ------------------ Trade and other liabilities 57 100 57 100 -------------------------------------- ------------------ ------------------ Loans and Borrowings 3 080 135 0 -------------------------------------- ------------------ ------------------ Deferred tax liability 515 354 260 169 -------------------------------------- ------------------ ------------------ Total liabilities 3 652 589 317 269 -------------------------------------- ------------------ ------------------ Current liabilities -------------------------------------- ------------------ ------------------ Trade and other liabilities 192 237 64 236 -------------------------------------- ------------------ ------------------ Loans and other borrowings 45 260 0 -------------------------------------- ------------------ ------------------ Total current liabilities 237 497 64 236 -------------------------------------- ------------------ ------------------ Net assets 23 282 172 13 545 097 -------------------------------------- ------------------ ------------------
Details of the main changes in the financial statements
Net assets amounted to EUR23.28 million, compared to EUR13.54 on December 31, 2023.
At December 31, 2024, the cash position was EUR1,000,0096 compared to EUR853,249 on December 31, 2023.
Financial key performance indicators 2024 2023 -------------------------------------------------- -------- ---------- NAV per share 37.05 33.00 -------------------------------------------------- -------- ---------- Earnings per share 0.96 -1.90 -------------------------------------------------- -------- ---------- Capital investment as a percentage of net assets 104.91% 94% -------------------------------------------------- -------- ---------- Profit/loss after tax 605 781 (781 564) -------------------------------------------------- -------- ----------
The share price as of 31 December 2024, at EUR43.20 remains stable despite there being considerable volatility in financial markets throughout the year.
Highlights of the year 2024
In 2024 HGO raised capital on three different occasions including an inaugural debt issue in US$ which not only provided liquidity but also due to the issuance in US$ provided a partial foreign exchange hedge. HGO also completed a follow-on investment in Gauzy Ltd prior to the company's listing on the NASDAQ stock exchange in the United States, as well as a first investment in an EU based company Antaria Pharma. This Euro denominated investment has also helped to balance the foreign exchange exposure in the portfolio.
GAUZY LTD is a world leading vendor of material science, focused on developing, manufacturing, and marketing LCG (light control glass) technology. Gauzy is the only company in the world working with two of the three active light control technologies, SPD (suspended particle device) and PDLC (polymer dispersed liquid crystals). Gauzy Ltd's LCG nanotechnologies allows glass to change from transparent to varying degrees of opaque on demand for privacy, custom shading, solar control, and transparent displays.
Antaria is a tech-enabled, alternative lending platform specialised in pharmacies. The company aims to become an end-to-end service provider, with a strategy based on upholding the principles of independent pharmacists and pharmacy ownership. Antaria's initial focus is pharmacies in France, and aspires to replicate its business model across Europe. Antaria aims to be the pharmacists' preferred partner across the spectrum, ranging from financing solutions to business management through the use of Antaria's proprietary technology platform.
About Hamilton Global Opportunities
Hamilton Global Opportunities plc ("HGO") is an investment holding company founded in 2009 and listed on the Euronext Growth Market in Paris since April 2021 that focuses on providing capital solutions to growth stage companies with a strong technology bias on a global basis. The HGO management team has significant relevant experience in structuring direct investments in the above mentioned areas. For more information, please visit: hamiltongo.eu
View source version on businesswire.com: https://www.businesswire.com/news/home/20250429291986/en/
CONTACT: Hamilton Global Opportunities
Gustavo Perrotta
Founder & CEO
gp@hamiltongo.eu
Gavin Alexander
Director & CRO
ga@hamiltongo.eu
NewCap
Theo Martin
Investor Relations
hamilton@newcap.eu
+33 (0)1 44 71 98 53
NewCap
Nicolas Merigeau
Media Relations
hamilton@newcap.eu
+33 (0)1 44 71 94 98
(END) Dow Jones Newswires
April 29, 2025 11:45 ET (15:45 GMT)
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。